{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:00:31Z","timestamp":1774375231516,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.beha.2021.101277","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T21:17:29Z","timestamp":1623187049000},"page":"101277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["New targets for CAR T therapy in hematologic malignancies"],"prefix":"10.1016","volume":"34","author":[{"given":"Malvi","family":"Savani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.beha.2021.101277_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clml.2019.09.598","article-title":"Recent advances in CAR-T cell therapy for non-hodgkin lymphoma","volume":"19","author":"Kallam","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"24","key":"10.1016\/j.beha.2021.101277_bib2","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.beha.2021.101277_bib3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.beha.2021.101277_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.beha.2021.101277_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","article-title":"The promise of CAR T-cell therapy in aggressive B-cell lymphoma","volume":"31","author":"Nair","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101277_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082030","article-title":"The great war of today: modifications of CAR-T cells to effectively combat malignancies","volume":"12","author":"Zhylko","year":"2020","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.beha.2021.101277_bib7","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Canc Res"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.beha.2021.101277_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Canc Discov"},{"issue":"26","key":"10.1016\/j.beha.2021.101277_bib10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beha.2021.101277_bib12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.beha.2021.101277_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101277_bib14","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2021.101277_bib15","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2021.101277_bib16","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Canc Discov"},{"issue":"5","key":"10.1016\/j.beha.2021.101277_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-all patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.beha.2021.101277_bib18","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2018-99-111368","article-title":"2-year follow-up and high-risk subset analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma","volume":"132","author":"Neelapu","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2021.101277_bib19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2021.101277_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Canc Cell"},{"issue":"7","key":"10.1016\/j.beha.2021.101277_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2021.101277_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1189\/jlb.5HI0716-322RR","article-title":"Frontline Science: functionally impaired geriatric CAR-T cells rescued by increased alpha5beta1 integrin expression","volume":"102","author":"Guha","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.beha.2021.101277_bib23","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"issue":"14","key":"10.1016\/j.beha.2021.101277_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136012","article-title":"A rational mouse model to detect on-target, off-tumor CAR T cell toxicity","volume":"5","author":"Castellarin","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.beha.2021.101277_bib25","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.blre.2019.05.002","article-title":"Cellular therapy for acute myeloid Leukemia - current status and future prospects","volume":"37","author":"Hansrivijit","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.beha.2021.101277_bib28","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101277_bib30","doi-asserted-by":"crossref","first-page":"569117","DOI":"10.3389\/fimmu.2020.569117","article-title":"Challenges and clinical strategies of CAR T-cell therapy for acute lymphoblastic leukemia: overview and developments","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-019-0758-x","article-title":"Target selection for CAR-T therapy","volume":"12","author":"Wei","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.beha.2021.101277_bib32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2021.101277_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","article-title":"High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy","volume":"120","author":"Rataj","year":"2019","journal-title":"Br J Canc"},{"issue":"12","key":"10.1016\/j.beha.2021.101277_bib35","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"14","key":"10.1016\/j.beha.2021.101277_bib37","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101277_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139087","volume":"136","author":"Baird","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.beha.2021.101277_bib41","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-019-0741-6","article-title":"Haploidentical CD19\/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Jia","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"511","key":"10.1016\/j.beha.2021.101277_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.beha.2021.101277_bib44","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.beha.2021.101277_bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101277_bib46","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101277_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene autoleucel (orva-cel; JCARH125): a fully human BCMA-targeted second-generation CAR T cell product characterized by a predominant central memory phenotype with high in vitro and in vivo proliferative potential and sustained in vivo persistence","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.beha.2021.101277_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.beha.2021.101277_bib49","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity","volume":"8","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.beha.2021.101277_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020321","article-title":"Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs)","volume":"9","author":"Hambach","year":"2020","journal-title":"Cells"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101277_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with cd123-specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101277_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-derived cd123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"10.1016\/j.beha.2021.101277_bib53","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.beha.2021.101277_bib55","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101277_bib56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142228","article-title":"CXCR4-Expressing anti-CD25 CAR T-cells effectively eliminate human AML cells in vivo","volume":"136","author":"Itoh-Nakadai","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101277_bib57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","article-title":"CD123 CAR T cells for the treatment of myelodysplastic syndrome","volume":"74","author":"Stevens","year":"2019","journal-title":"Exp Hematol"},{"key":"10.1016\/j.beha.2021.101277_bib58","doi-asserted-by":"crossref","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.beha.2021.101277_bib60","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.bbmt.2019.12.482","article-title":"CD5 CAR T-cells for treatment of patients with relapsed\/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity","volume":"26","author":"Hill","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101277_bib62","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2020.38.15_suppl.3026","article-title":"First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma","volume":"38","author":"Zhang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2021.101277_bib63","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2019-122789","article-title":"First-in-Human CD4 CAR clinical trial on peripheral T-cell lymphoma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101277_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T cell malignancies using CD4CAR T-cells and implementing a natural safety switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"32","key":"10.1016\/j.beha.2021.101277_bib66","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2021.101277_bib67","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Canc Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:46Z","timestamp":1761498406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521692621000426"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101277","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New targets for CAR T therapy in hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101277"}}